U.S., Jan. 31 -- ClinicalTrials.gov registry received information related to the study (NCT06801158) titled 'Adverse Drug Reactions to Cancer Therapies in Patients with Depression: Insights from VigiBase' on Jan. 24.
Brief Summary: Importance:
Depression is prevalent among oncology patients and may influence the perception, reporting, and severity of adverse events (AEs) related to cancer therapies. Understanding this association is crucial for optimizing treatment outcomes and improving patient quality of life.
Objective:
To evaluate the association between depression and the reporting and severity of AEs among oncology patients using data from VigiBase(R), the World Health Organization's global pharmacovigilance database.
Design:
Th...